Skip to main content
Navigate Up
Sign In
 

MS/Neuroimmunology

Clinical Research



If you think you may qualify for one of these studies, please contact Professional Research Assistant (PRA) below for more information.

Search for: view all

COMIRB # Title (Please click on the title to see approved advertisement) Principal Investigator PRA
12-0968 Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders Alvarez, Enrique, MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
15-1194 A Phase II, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Multi-Dose Intravitreal Injections to Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION) Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
16-0120 AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
14-0926 A Phase 2/3, Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Eligibility and Information
13-3181 Collaborative International Research in Clinical and Longitudinal Experience for Neuromyelitis Optica (NMO) Studies (CIRCLES) Bennett, Jeffrey L., MD, PhD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
15-2388 Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) (DISCOMS) Corboy, John R., MD Nicola Haakonsen
303-724-4644
Eligibility and Information
08-0613 The role of TH40 cell in Multiple Sclerosis and Type 1 Diabetes Corboy, John R., MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
09-0952 Rocky Mountain MS Center Tissue Bank Corboy, John R., MD Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
16-0121 Multi-center, randomized, double-blinded assessment of Tecfidera® in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE) Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
16-0156 Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Eligibility and Information
12-1084 Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
12-1102 Pediatric Multiple Sclerosis and other Demyelinating Diseases Database (PeMSDD Database) Schreiner, Teri L., MD, MPH Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information
16-2178 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) (POINT) Vollmer, Timothy L., MD Nicola Haakonsen
303-724-4644
Eligibility and Information
16-1221 A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis Vollmer, Timothy L., MD Nicola Haakonsen
303-724-4644
Eligibility and Information
Comparative Effects of Glatiramer Acetate and BG0012 on lymphocyte survival and metabolism Vollmer, Timothy L., MD
Greg Owens, PhD
Nicola Haakonsen
303-724-4644
Please contact PRA for eligibility and information